|
 |
 |
 |
|
|
.: Дата публікації 2009-06-25 :: Переглядів: 8 ::  :.
Agonists of dopaminergic receptors (Mirapex) in complex pathogenetic therapy of Parkinson's disease
I.N. KARABAN, Yu.I. GOLOVCHENKO, N.V. KARABAN, T.N. KALISHCHUK-SLOBODIN, N.V. KARASEVYCH
Purpose – to evaluate the effectiveness of Pramipexol (Mirapex) course treatment of Parkinson's disease (PD) in patients on different disease stages.
Methods and subjects. Forty-six PD patients, 1.5–3.0 scores, Hoehn- a. Yahr stage scale, at age range from 49 to 74 years were examined. Average daily dosage of Mirapex was 1.0–2.5 mg. Motor activity was assessed according to the UPDRS scale. Luria's test, Spilberger's scale and Beck's depressivity scale were also used. The state of free radical oxidation was determined by means of lipids (malonic aldehyde, catalase, superoxidodismutase, antioxidant factor) peroxide oxidation.
Results. The drug Mirapex has turned out to be highly effective both in mono therapy at initial disease stages and in complex pathogenetic therapy against the background of stable use of levodopa-containing drugs. It had a positive effect on the main clinical PD symptoms, especially on tremor, mnestic function and depression. The statistic
dynamics against background of free radical oxidation indicates antioxidant action of the drug.
Conclusions. Effects of Mirapex on the pronouncement of levodopa-evoked fluctuations and dyskinesias evidences the topic action of the drug on D1-mediated neurotransmitter pathway and, consequently, diminution of imbalance between activities of direct and indirect motor pathways.
Ключові слова: Parkinson's disease, pramipexol (Mirapex).
.: назад :.
|
|
 |
|
 |
|
|
